Sanofi Consumer Healthcare Q1 profit rises 13.3% to ₹68.8 crore; revenue up 6.7%

Sanofi Consumer Healthcare India reported a 13.3% year-on-year increase in net profit for the quarter ended June 30, 2026 (Q1FY27), driven by healthy domestic demand and improved operating performance. The company also reported a sharp expansion in margins as revenue growth was supported by the continued recovery of products relaunched after last year’s precautionary recall.

Net profit stood at ₹68.8 crore, compared with ₹60.7 crore in the year-ago period. Revenue from operations rose 6.7% to ₹235.7 crore from ₹220.9 crore a year earlier. EBITDA increased 27.2% to ₹89.3 crore, while EBITDA margin expanded to 37.9% from 31.8% in the corresponding quarter last year.

Profit before tax rose 16.5% to ₹91.9 crore from ₹78.9 crore a year ago, while earnings per share increased to ₹29.87 from ₹26.36.

Domestic business fuels growth

The company said domestic sales grew 12% year-on-year during the quarter, aided by the relaunch of products that had been voluntarily recalled in 2024. Export sales, however, declined 9% on a high base.

For the first half of the calendar year, revenue from operations rose 18% to ₹464.9 crore, while profit before tax increased 25% to ₹182.6 crore, reflecting continued momentum across its consumer healthcare portfolio.

Management remains optimistic

Commenting on the performance, Himanshu Bakshi, managin director, Sanofi Consumer Healthcare India Ltd, said, “Our performance this quarter reflects the disciplined execution on all fronts. Our targeted investments behind our brands and go-to-market capabilities are translating into profitable growth and market share gains in most of our brands, reinforcing our confidence in the strength of our strategy.”

Shares of Sanofi Consumer Healthcare ended Tuesday’s session 0.34% higher at ₹4,701 apiece on the NSE. The stock has declined more than 5% over the past year, broadly in line with the benchmark Nifty 50, which has fallen nearly 3% during the same period.